Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Raynaud

Showing results (141-150 of 211) with videos related to

Pageof 22
Sort By:
The Prostate|January 1, 1993
Multivariate analysis of plasma hormones in patients with metastatic prostate cancer receiving combined LHRH-analog and antiandrogen therapyJ Fiet, J C Doré, A L Gô, et al.
Cancer Research|January 1, 1977
High inhibitory activity of a new antiestrogen, RU 16117 (11alpha-methoxy ethinyl estradiol), on the development of dimethylbenz(a)anthracene-induced mammary tumorsP A Kelly, J Asselin, M G Caron, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1984
Animal models for hormone-dependent human breast cancer. Relationship between steroid receptor profiles in canine and feline mammary tumors and survival rateP M Martin, M Cotard, J P Mialot, et al.
Journal of Steroid Biochemistry|January 1, 1987
Towards the mapping of the progesterone and androgen receptorsT Ojasoo, J Delettré, J P Mornon, et al.
Journal of Steroid Biochemistry|May 1, 1979
Specific binding of [3H]-methyltrienolone to both progestin and androgen binding components in human benign prostatic hypertrophy (BPH)J Asselin, R Mélançon, Y Gourdeau, et al.
Journal of the National Cancer Institute|March 1, 1977
Potent inhibitory effect of a new antiestrogen (RU 16117) on the growth of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumorsP A Kelly, J Asselin, M G Caron, et al.
European Urology|April 29, 1998
Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsiesM Paubert-Braquet, H Cousse, J P Raynaud, et al.
The Journal of Steroid Biochemistry and Molecular Biology|September 1, 1995
Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitorsC Iehlé, S Délos, O Guirou, et al.
The Prostate|January 1, 1984
The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a reviewJ P Raynaud, C Bonne, M Moguilewsky, et al.
Molecular and Cellular Endocrinology|January 1, 1981
Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the ratC Séguin, L Cusan, A Bélanger, et al.
Pageof 22

Showing results (141-150 of 211) with videos related to

Sort By:
Pageof 22
The Prostate|January 1, 1993
Multivariate analysis of plasma hormones in patients with metastatic prostate cancer receiving combined LHRH-analog and antiandrogen therapyJ Fiet, J C Doré, A L Gô, et al.
Cancer Research|January 1, 1977
High inhibitory activity of a new antiestrogen, RU 16117 (11alpha-methoxy ethinyl estradiol), on the development of dimethylbenz(a)anthracene-induced mammary tumorsP A Kelly, J Asselin, M G Caron, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1984
Animal models for hormone-dependent human breast cancer. Relationship between steroid receptor profiles in canine and feline mammary tumors and survival rateP M Martin, M Cotard, J P Mialot, et al.
Journal of Steroid Biochemistry|January 1, 1987
Towards the mapping of the progesterone and androgen receptorsT Ojasoo, J Delettré, J P Mornon, et al.
Journal of Steroid Biochemistry|May 1, 1979
Specific binding of [3H]-methyltrienolone to both progestin and androgen binding components in human benign prostatic hypertrophy (BPH)J Asselin, R Mélançon, Y Gourdeau, et al.
Journal of the National Cancer Institute|March 1, 1977
Potent inhibitory effect of a new antiestrogen (RU 16117) on the growth of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumorsP A Kelly, J Asselin, M G Caron, et al.
European Urology|April 29, 1998
Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsiesM Paubert-Braquet, H Cousse, J P Raynaud, et al.
The Journal of Steroid Biochemistry and Molecular Biology|September 1, 1995
Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitorsC Iehlé, S Délos, O Guirou, et al.
The Prostate|January 1, 1984
The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a reviewJ P Raynaud, C Bonne, M Moguilewsky, et al.
Molecular and Cellular Endocrinology|January 1, 1981
Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the ratC Séguin, L Cusan, A Bélanger, et al.
Pageof 22